Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Clinical Trial

Published on 01 Feb 2024

Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectives

in Pharmacology of Anti-Cancer Drugs

Zhichao Tian
Yushen Feng
Yang Yang
Xu Liu
Guoxin Qu
Yonghao Yang
Xin Wang
Jiaqiang Wang
Peng Zhang
Weitao Yao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1335054

2,200 views
2 citations

Case Report

Published on 01 Feb 2024

Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic gastric mixed neuroendocrine-non-neuroendocrine tumor: a case report

in Pharmacology of Anti-Cancer Drugs

Lingnan Zheng
Lingqi Sun
Ji Ma

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1295134

1,864 views
1 citation

Original Research

Published on 01 Feb 2024

Alpha-hederin reprograms multi-miRNAs activity and overcome small extracellular vesicles-mediated paclitaxel resistance in NSCLC

in Pharmacology of Anti-Cancer Drugs

Yuzhen Chang
Xinyu Gao
Yuchen Jiang
Jingyi Wang
Liu Liu
Jun Yan
Gang Huang
Hao Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1257941

3,210 views
3 citations

Review

Published on 01 Feb 2024

Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma

in Pharmacology of Anti-Cancer Drugs

Jiao Wang
Chengyu Liu
Ronghua Hu
Licheng Wu
Chuanzhou Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1324140

5,789 views
7 citations

Original Research

Published on 31 Jan 2024

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis

in Pharmacology of Anti-Cancer Drugs

Zhiwei Cui
Zhen Zhai
De Xie
Lihui Wang
Feiyan Cheng
Siyu Lou
Fan Zou
Rumeng Pan
Shixue Chang
Haoyan Yao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1329409

4,090 views
5 citations

Review

Published on 31 Jan 2024

Research progress on cuproptosis in cancer

in Pharmacology of Anti-Cancer Drugs

Qingbo Feng
Chenyu Huo
Maijian Wang
Handong Huang
Xingbin Zheng
Ming Xie

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1290592

5,525 views
15 citations

Original Research

Published on 29 Jan 2024

Mechanisms underlying the therapeutic effects of cinobufagin in treating melanoma based on network pharmacology, single-cell RNA sequencing data, molecular docking, and molecular dynamics simulation

in Pharmacology of Anti-Cancer Drugs

Jiansheng Yang
Chunchao Cheng
Zhuolin Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1315965

5,990 views
3 citations

Review

Published on 25 Jan 2024

The application of peroxidase mimetic nanozymes in cancer diagnosis and therapy

in Pharmacology of Anti-Cancer Drugs

Amin Moradi Hasan-Abad
Atefe Shabankare
Amir Atapour
Gholam Ali Hamidi
Mahmoud Salami Zavareh
Ali Sobhani-Nasab

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1339580

3,949 views
5 citations

Original Research

Published on 25 Jan 2024

Prediction of initial objective response to drug-eluting beads transcatheter arterial chemoembolization for hepatocellular carcinoma using CT radiomics-based machine learning model

in Pharmacology of Anti-Cancer Drugs

Xueying Zhang
Zijun He
Yucong Zhang
Jian Kong

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1315732

2,412 views
5 citations

Original Research

Published on 25 Jan 2024

Antitumor efficacy of silver nanoparticles reduced with β-D-glucose as neoadjuvant therapy to prevent tumor relapse in a mouse model of breast cancer

in Pharmacology of Anti-Cancer Drugs

Moisés Armides Franco Molina
David Reding Hernández
Paola Leonor García Coronado
Jorge R. Kawas
Diana G. Zárate Triviño
Sara Paola Hernández Martínez
Beatriz Elena Castro Valenzuela
Cristina Rodríguez Padilla

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1332439

2,183 views
2 citations

Review

Published on 24 Jan 2024

Hypoxia inducible factor-1ɑ as a potential therapeutic target for osteosarcoma metastasis

in Pharmacology of Anti-Cancer Drugs

Jianghu Zhou
Fengjun Lan
Miao Liu
Fengyan Wang
Xu Ning
Hua Yang
Hong Sun

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1350187

2,890 views
12 citations

Original Research

Published on 24 Jan 2024

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)

in Pharmacology of Anti-Cancer Drugs

Yiwen Bao
Jiaju Chen
Luting Duan
Fujue Wang
Han Lai
Zeming Mo
Weiliang Zhu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1288362

4,144 views
5 citations

Systematic Review

Published on 24 Jan 2024

Sustained efficacy of chimeric antigen receptor T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis of individual data

in Pharmacology of Anti-Cancer Drugs

Jing Zhou
Zhenhao Wang
Hanyu Wang
Yang Cao
Gaoxiang Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1331844

2,229 views
2 citations

Review

Published on 23 Jan 2024

GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs

in Pharmacology of Anti-Cancer Drugs

Qingzhi Ji
Huimin Zhu
Yuting Qin
Ruiya Zhang
Lei Wang
Erhao Zhang
Xiaorong Zhou
Run Meng

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1329636

7,372 views
28 citations

Systematic Review

Published on 23 Jan 2024

A global bibliometric and visualized analysis of the links between the autophagy and acute myeloid leukemia

in Pharmacology of Anti-Cancer Drugs

Yao Gao
Zhenhui Wu
Yingfan Chen
Guangbin Shang
Yingjian Zeng
Yue Gao

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1291195

4,932 views
4 citations

Systematic Review

Published on 22 Jan 2024

The efficacy of bevacizumab combined with platinum-containing chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review and meta-analysis of randomized clinical trials

in Pharmacology of Anti-Cancer Drugs

Guangsu Han
Chenlu Li
Ping Yi

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1293039

2,001 views
1 citation